hydroxyurea

P2, N=153, Recruiting, RTOG Foundation, Inc. | Not yet recruiting --> Recruiting

Herein, we report two such novel 3D coordination polymers of zinc-inosine-5'-monophosphate (Zn-IMP) and bpe/azpy (as linkers) which were engineered as metal-organic frameworks that can be used as drug carriers for hydroxyurea (HU)...Across acidic pH, for CP-1 the ligand RMSD increases markedly and U becomes slightly less negative, which indicated partial loss of contacts, thus releasing drugs in a tumor-like environment more easily. These result showed that CP-1 offers stronger binding, higher structural stability and a more pronounced pH-responsive release profile than CP-2, making CP-1 more promising candidate for targeted HU drug delivery, while CP-2 may serve as a weaker-binding, faster-release complement.

Severe anemia and neutropenia induced by R788 in the sickle mouse model suggests that concomitant use of Syk inhibitors with hydroxyurea in patients with SCD should be approached cautiously. Further research is required to clarify the benefits and risks of selective Syk inhibition in SCD and other hemolytic conditions exhibiting stress hematopoiesis.

P1/2, N=29, Recruiting, Washington University School of Medicine | Trial completion date: Apr 2031 --> Apr 2033 | Trial primary completion date: Apr 2026 --> Apr 2028

Treatment comprised phlebotomy, low-dose aspirin, hydroxyurea, and statin therapy. Ischemic stroke can be the initial presentation of JAK2-positive erythrocytosis consistent with polycythemia vera. Careful framing of diagnostic certainty, early hematocrit control, antithrombotic therapy, and risk-factor optimization are key, especially where resources are limited.

PARP1 and MnSOD were upregulated, but not OGG1, which indicates GRE's selective action. Our findings confirm its genoprotective effects against hydroxyurea-induced DNA damage in peripheral blood mononuclear cells, indicate a complex mechanism of action, and call for further research of this promising compound against secondary genotoxic effects of hydroxyurea.

Treatment for polycythemia vera included hydroxyurea. Methotrexate and sulfasalazine were prescribed for rheumatoid arthritis but were withdrawn due to intolerance, and therapy was switched to tofacitinib 5 mg twice daily...After 12 months of therapy, RA remission persisted without adverse events or cytopenias. Tofacitinib demonstrated rheumatologic efficacy but minimal effect on PV-related hematologic activity.

Initial treatment with hydroxyurea and leukapheresis followed by azacitidine and venetoclax resulted in an inadequate treatment response. Given the lack of research on the FLT3 V491L mutation, we conducted an ex vivo sensitivity study using the patient's diagnostic bone marrow blasts to assess and compare the anti-leukemic efficacy of midostaurin, quizartinib, and gilteritinib...Treatment of relapsed AML with a non-canonical mutation is challenging due to the lack of data regarding FLT3 inhibitors. This case highlights the potential role of gilteritinib in targeting the rare FLT3 V491L mutation, underscoring the need for further research and improved accessibility to effective therapies.

P2, N=96, Completed, Novo Nordisk A/S | Trial primary completion date: Dec 2024 --> Jul 2025

The patient fully recovered and completed induction without complications. This case highlights the importance of recognizing CS as a rare presenting feature of leukemia, and supports hydroxyurea bridging as a viable strategy when immediate chemotherapy is contraindicated to support surgical recovery.

The patient was managed with drugs such as hydroxyurea, antiplatelet drugs, and phlebotomy. The most notable feature of this intriguing case is PV manifesting as idiopathic intracranial hypertension and vision loss despite normal patent sinuses, which is explainable by hypercoagulability causing sluggish flow in venous sinuses and raised pressure over the optic nerves, resulting in papilledema and vision loss.

P1, N=26, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting